Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan

• DOI: 10.1007/s12185-020-03008-3
• Publication Date: 2020-09-24T12:02:39Z
• Authors: Shino Fujimoto; Hiroshi Kawabata; Tomoyuki Sakai; Hiroto Yanagisawa; Momoko Nishikori; Kenji Nara; Shin Ohara; Norifumi Tsukamoto; Nozomu Kurose; Sohsuke Yamada; Kazue Takai; Sadao Aoki; Yasufumi Masaki
• Keywords: Adult; Aged, 80 and over; Male; Salvage Therapy; Castleman Disease; Middle Aged; Antibodies, Monoclonal, Humanized; 3. Good health; Survival Rate; Young Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Japan; Adrenal Cortex Hormones; Cyclosporine; Humans; Female; Treatment Failure; Rituximab; Aged; Retrospective Studies

TAFRO syndrome is a systemic inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Mortality in patients with this syndrome is high; however, an optimal treatment strategy has not been established. To explore the strategy, we retrospectively analyzed 81 patients with TAFRO syndrome registered in the Multicenter Collaborative Retrospective Study for Establishing the Concept of TAFRO Syndrome in Japan by December 2019. Sixty-eight patients received corticosteroid therapy as the first-line treatment, and as the second-line treatment, 21 received tocilizumab (Toc), 14 received cyclosporine A (CsA), and 8 received rituximab (Rit) in addition to corticosteroids. We compared these second-line treatment groups by setting the primary endpoint as time to next treatment or death (TTNT). Kaplan-Meier analysis showed that the median TTNT in the Toc, CsA, and Rit groups were 2.8 months, 9.2 months, and not reached, respectively. The TTNT of the Rit group was significantly longer than that of the Toc group. In contrast, there were no significant differences in overall survival between groups, indicating that subsequent salvage therapies rescued a large proportion of patients who failed the second-line treatments. Further studies are warranted to establish the optimal treatment strategies for this syndrome.